









Markets
/
Stocks
/
nasdaq-enta
/

Enanta Pharmaceuticals Inc

ENTA

13.510USD

+0.540+4.16%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

288.94MMarket Cap

LossP/E TTM



Enanta Pharmaceuticals Inc

13.510

+0.540+4.16%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Enanta Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Enanta Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.12.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Enanta Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

68 / 159

Overall Ranking

183 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Enanta Pharmaceuticals Inc Highlights

StrengthsRisks

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Growing

The company is in a growing phase, with the latest annual income totaling USD 65.32M.

Undervalued

The company’s latest PE is -3.52, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 19.84M shares, increasing 6.96% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.90K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

19.125

Target Price

+47.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Enanta Pharmaceuticals Inc is 7.30, ranking 119 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 15.12M, representing a year-over-year increase of 3.55%, while its net profit experienced a year-over-year increase of 35.12%.

Score

Industry at a Glance

Previous score

7.30

Change



Financials

4.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.37

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.23

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Enanta Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Enanta Pharmaceuticals Inc is 7.10, ranking 99 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -3.52, which is -73.34% below the recent high of -0.94 and -166.24% above the recent low of -9.37.

Score

Industry at a Glance

Previous score

7.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Enanta Pharmaceuticals Inc is 8.25, ranking 50 out of 159 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 28.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

19.125

Target Price

+47.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Enanta Pharmaceuticals Inc

ENTA

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Enanta Pharmaceuticals Inc is 6.77, ranking 107 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 14.30 and the support level at 12.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.40

Change

0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.185

Neutral

RSI(14)

51.347

Neutral

STOCH(KDJ)(9,3,3)

75.127

Neutral

ATR(14)

0.632

Low Volatility

CCI(14)

133.459

Buy

Williams %R

25.066

Buy

TRIX(12,20)

-0.369

Sell

StochRSI(14)

91.803

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

13.344

Buy

MA10

13.107

Buy

MA20

13.045

Buy

MA50

14.046

Sell

MA100

12.389

Buy

MA200

9.768

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Enanta Pharmaceuticals Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 81.86%, representing a quarter-over-quarter decrease of 29.86%. The largest institutional shareholder is The Vanguard, holding a total of 2.30M shares, representing 7.93% of shares outstanding, with 15.53% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.94M

-1.91%

Farallon Capital Management, L.L.C.

2.12M

Krensavage Asset Management, LLC

2.11M

Janus Henderson Investors

1.95M

+271.73%

BlackRock Institutional Trust Company, N.A.

1.57M

-0.40%

Deep Track Capital LP

1.48M

Acadian Asset Management LLC

867.04K

Luly (Jay R)

820.10K

-0.80%

Commodore Capital LP

800.00K

Millennium Management LLC

948.08K

-35.00%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Enanta Pharmaceuticals Inc is 4.96, ranking 79 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.